Generic correspondence
Executive Summary
FDA Office of Generic Drugs requests that all ANDAs, AADAs, amendments and supplements mailed to the agency via the U.S. Postal Service be addressed to: Office of Generic Drugs, CDER, FDA, MPN II, HFD-600, 5600 Fishers Lane, Rockville, MD, 20857. Correspondence not associated with an application should be sent to the same address with the division, person and appropriate HFD- code specified. Only parcel post or overnight courier service should be addressed to: Office of Generic Drugs, CDER, FDA, Metro Park North II, 7500 Standish Pl., Room 150, Rockville, MD, 20855.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth